Here's the schedule for the upcoming Age Management Conference that pertains to stem cell therapy. Track 3 is on Sunday.
Clinical Applications for
Age Management Medicine Conference
November 11-14, 2010
M Resort & Spa, Las Vegas, Nevada
Pre-Conference Track 3: Regenerative and Cell Based Medicine
Regenerative and cell based medicine continue to grow in use by physicians across the world. From platelet rich plasma to culture expanded stem cells, the need for information about the applications of these therapies to treat patients has never been greater. Sponsored by the International Cellular Medicine Society, a global nonprofit with over a thousand members from 35 countries is dedicated to physician education and patient safety, this track will focus on the latest developments in cell based medicine with speakers who are driving the research and using these technologies as part of their everyday practice of medicine. This track will present presentations on the use of PRP, adipose, bone marrow and peripheral blood derived stem cells and data on the application of these promising therapies in providing treatment to patients today.
Academic Supporter: International Cellular Medicine Society (ICMS)
Co -Chairs: Christopher J. Centeno, M.D.
L. Stephen Coles, M.D., Ph.D.
8:00 am ? 8:10 am
Opening Remarks and Overview of the ICMS Educational Mission
David Audley
Executive Director, International Cellular Medicine Society (ICMS)
8:10 am - 8:45 am
The Current State of Adult Autologous Stem Cell Therapy-Results and Finding from the International Cellular Medicine Society Treatment Registry
Michael D. Freeman, Ph.D., M.P.H.,
Clinical Professor of Epidemiology, Department of Public Health and Preventive Medicine, Oregon Health & Sciences University School of Medicine
Adjunct Associate Professor of Forensic Medicine and Epidemiology, Institute of Forensic Medicine, Faculty of Health Sciences, University of Aarhus, Aarhus, Denmark
President, International Cellular Medicine Society (ICMS)
Dr. Freeman will describe the current outcome and complication results in the ICMS treatment registry, the largest surveillance and analysis database for therapy involving adult autologous stem cells in existence.
8:45 am - 9:20 am
Stem Cells in the Nervous System: Data on the Applications of Bone Marrow Aspirant Concentrate
Augusto Brazzini, M.D.
Professor, San Martin University, Lima Peru
Director, Brazzini Institute of Interventional Radiology
Vice President, Asociacion Peruana de Terapia Cellular (APTCEL)
The use of autologous bone marrow aspirate concentrate to treat Parkinson's disease will be discussed. Case reports of patients before and after treatment will be highlighted.
9:20 am - 10:00 am
Adipose Tissue Derived Stem Cells
Ricardo L. Rodriquez, M.D.
Clinical Instructor, Johns Hopkins University
Medical Director, Cosmeticsurg.net, Luthersville, MD
This lecture is a brief overview of the refinements in technique that have enabled the use of Adipose Tissue as reliable tissue graft material. Since Adipose tissue is the most abundant and easily accesible source of Mesenchymal stem cells, it has applications in Plastic Surgery both as a structural graft and regenerative agent. We will review some applications of Adipose Derived Stem Cells in the field of Plastic Surgery.
10:00 am - 10:15 am
Break
10:15 am - 10:50 am
Basic Stem Cell Line Development: What are the Stem Cells we will be Using in the Next 5 Years?
Yael Porat, Ph.D.
Founder / CEO, BiogenCell, Ltd., Netaya, Israel
The identification of new stem cells types is important to allow physicians to have new tools to treat patients. This lecture will focus on basic stem cell biology including the process of how new stem cells lines are identified and tested.
10:50 am ? 11:35 am
Heart Failure Improvement with Minimal Invasive Delivery of Stem Cell
Jorge Tuma Mubarak, M.D.
Chairman, International Cardiology and Regenerative Medicine, Maison De Sante Clinic, Lima, Peru
Member, Latin American Society of Interventional Cardiology and Latin American Society of Stem Cell Therapy
4 Year follow up reporting on successful retreatment of refractory angina by the use of minimally invasive delivery of stem cells.
11:35 am - 12:15 pm
Bone Marrow Derived Stem Cells In The Treatment Of Diabetes Type 1
Alejandro D. Mesples, M.D.
Interventional Cardiologist Associate Professor of Clinical Research Service, University of Moron, School of Medicine, Argentina
Scientific Advisor and Principal Investigator, Stematix, Houston, TX
The use of bone marrow aspirate concentrate to treat type II and type I diabetes will be discussed. Serum glucose and H1AC levels before and after treatment will be highlighted.
12:15 pm - 1:15 pm
Regulatory Landscape in 2011
Christine Humphrey, Esq and Mitchell Fuerst, Esq
Fuerst, Humphrey & Ittleman Law Firm, Miami, FL
Non-CME Invitation Only Lunch Symposium Sponsored By:
1:15 pm ? 1:45 pm
Improvement After Reimplantation and Parkinson?s Disease Patient Characteristics: Analysis for the Relationships (Relation and Correlation) Between Improvement After reimplantation of Adult Autologpus Bone Marrow Mononuclear Portion Versus Age of Implant, Time of Disease and Age at Diagnosis for Parkinson?s Disease Patients
Tamara Jorquiera, M.D.
Professor, San Martin University, Lima Peru
Physician Researcher, Brazzini Institute of Interventional Radiology
Founding Member, Asociacion Peruana de Terapia Cellular (APTCEL)
The improvements in Parkinson's disease patients after treatment with bone marrow aspirate concentrate will be discussed as well as the correlation between age of implant, time of disease onset, and patient age with treatment success.
1:45 pm ? 2:15 pm
A Validated Method for the Isolation of Adipose Derived Stem Cells and Their Importance in Autologous Fat Graft Survival
Kristin Comella
CEO, Stemlogix, Fort Lauderdale, FL
Chief Scientific Officer, Ageless Regenerative Institute
VP Research & Corporate Development, BioHeart, Inc.
Recent studies have identified adipose tissue as an alternate source of stem cells. The procedure for obtaining adipose derived stem cells (ADSCs) from the patient is a relatively simple process and tolerated by most patients. Fat tissue can usually be found in abundance within the patient?s own body and has a greater number of stem cells than bone marrow. ADSCs can be used at the site of injury or disease, as well as for soft tissue defects and fat transfer. Regenerative cells may amplify the body?s own repair process, accelerate healing, repair damaged and diseased tissue, and prevent scarring and loss of function. ADSCs have demonstrated angiogenic properties and can provide a practical approach to tissue vascularization. We have developed a standardized harvesting process for adipose tissue and the isolation of ADSCs. This advancement in collection of ADSCs makes the procedure more predictable and reliable, which is especially important in treatment of degenerative diseases. These techniques are currently being utilized in the clinic for a variety of indications.
2:15pm - 2:45pm
How Very Small Embryonic Like Stem Cells Shed New Light on Mesenchymal Stem Cell Function - New data supports Role of VSELs TM In The Regenerative Properties of MSCs
Alan G. Harris, M.D., Ph.D.
Vice President Drug Development & Regulatory Affairs, Neostem, New York, NY
Adult multipotent stem cells such as Mesenchymal Stem Cells (MSCs) can differentiate into a limited number of cell types, thus permitting autologous cell-based therapy. This has advantages over human embryonic stem cells (hESC) with no risk of rejection and quicker engraftment. Recently discovered Very Small Embryonic-Like, (VSEL) adult stem cells can be obtained from mobilization and apheresis of autologous peripheral blood thus avoiding the need for bone marrow aspiration.
Current studies suggest that VSELs are true pluripotent stem cells with most of the beneficial, and none of the drawbacks (eg. tumorigenesis), of hESCs or induced pluripotent stem cells. New data supports a role of VSELs in the regenerative properties of MSCs. Unlike other ASCs, pluripotent VSELs can be used for a wide range of therapeutic applications.
Small numbers of VSELs can provide adequate cell doses and are expandable, if necessary, and can be cryopreserved to provide a banked source for multiple regenerative treatments over time, thereby providing a lifelong deposit of pluripotent stem cells. Therapeutic applications of VSELs are being considered in wounds, bone and cartilage repair, cardiovascular diseases and other conditions.
2:45 pm ? 3:15pm
The Use of Mesenchymal Stem cells in Lumbar Degenerative Disc Disease
John R. Schultz, M.D., D.A.B.P.M.
Co-Medical Director, Centeno-Schultz Clinic, Westminster, CO
The results of a 5 year study of the use of BMAC and two different preparations of mesenchymal stem cells to treat lumbar disc bulges will be presented. Before and after high filed MRI's will be reviewed as well as patient reported outcomes will be reviewed.
3:15 pm ? 4:00 pm
Break - Visit Exhibits
4:00 pm - 4:30 pm
Large Scale Outcomes From Peripheral Joint Treatments: Follow Up From the Orthopedic Use of MSCs
Christopher J. Centeno, M.D.
Medical Director, Centeno-Schultz Clinic & Regenerative Science
The lecture will focus on the use of culture expanded mesenchymal stem cells in orthopedics and how percutaneous delivery of these cells can help patient avoid the need for more invasive surgery. Large scale complications will be discussed as well as large case series for knee a hip osteoarthritis outcomes.
4:30 pm ? 4:45pm
Clinical Use of a Single-Setting Autologous Adipose-Derived Stromal Cells Procedure: Lessons Learned To Date
Vasilis Paspaliaris, MD
Director / Founder, Adistem, Hong Kong
Visiting Professor, Institute of Integrative medicine, Indian Open University, Calcutta, India
The presentation will give an introduction into the procedure, how it has evolved into a clinical setting over four years, and where its medical benefits and limitations lie. It will conclude with what the outcome of such clinical research has been.
4:45 pm - 5:30 pm
Adipose Derived Adult Stem Cells: History, Current Use and Future Developments in treating Critical Lim Ischemia
Jeong Chan Ra, D.V.M., Ph.D.
Adjunct Professor, College of Veterinary Medicine, Seoul National University, Seoul South Korea
CEO, RNL Bio Ltd., Seoul, Korea
Adipose derived MSC's hold great promise for regenerative medicine. The use of culture expanded MSC's to treat critical limb ischemia and help patients avoid amputation will be discussed. Before and after photos of treated limbs and vascular studies will be reviewed.
6:00 pm
ICMS Member Meeting & Member Reception
Clinical Applications for
Age Management Medicine Conference
November 11-14, 2010
M Resort & Spa, Las Vegas, Nevada
Pre-Conference Track 3: Regenerative and Cell Based Medicine
Regenerative and cell based medicine continue to grow in use by physicians across the world. From platelet rich plasma to culture expanded stem cells, the need for information about the applications of these therapies to treat patients has never been greater. Sponsored by the International Cellular Medicine Society, a global nonprofit with over a thousand members from 35 countries is dedicated to physician education and patient safety, this track will focus on the latest developments in cell based medicine with speakers who are driving the research and using these technologies as part of their everyday practice of medicine. This track will present presentations on the use of PRP, adipose, bone marrow and peripheral blood derived stem cells and data on the application of these promising therapies in providing treatment to patients today.
Academic Supporter: International Cellular Medicine Society (ICMS)
Co -Chairs: Christopher J. Centeno, M.D.
L. Stephen Coles, M.D., Ph.D.
8:00 am ? 8:10 am
Opening Remarks and Overview of the ICMS Educational Mission
David Audley
Executive Director, International Cellular Medicine Society (ICMS)
8:10 am - 8:45 am
The Current State of Adult Autologous Stem Cell Therapy-Results and Finding from the International Cellular Medicine Society Treatment Registry
Michael D. Freeman, Ph.D., M.P.H.,
Clinical Professor of Epidemiology, Department of Public Health and Preventive Medicine, Oregon Health & Sciences University School of Medicine
Adjunct Associate Professor of Forensic Medicine and Epidemiology, Institute of Forensic Medicine, Faculty of Health Sciences, University of Aarhus, Aarhus, Denmark
President, International Cellular Medicine Society (ICMS)
Dr. Freeman will describe the current outcome and complication results in the ICMS treatment registry, the largest surveillance and analysis database for therapy involving adult autologous stem cells in existence.
8:45 am - 9:20 am
Stem Cells in the Nervous System: Data on the Applications of Bone Marrow Aspirant Concentrate
Augusto Brazzini, M.D.
Professor, San Martin University, Lima Peru
Director, Brazzini Institute of Interventional Radiology
Vice President, Asociacion Peruana de Terapia Cellular (APTCEL)
The use of autologous bone marrow aspirate concentrate to treat Parkinson's disease will be discussed. Case reports of patients before and after treatment will be highlighted.
9:20 am - 10:00 am
Adipose Tissue Derived Stem Cells
Ricardo L. Rodriquez, M.D.
Clinical Instructor, Johns Hopkins University
Medical Director, Cosmeticsurg.net, Luthersville, MD
This lecture is a brief overview of the refinements in technique that have enabled the use of Adipose Tissue as reliable tissue graft material. Since Adipose tissue is the most abundant and easily accesible source of Mesenchymal stem cells, it has applications in Plastic Surgery both as a structural graft and regenerative agent. We will review some applications of Adipose Derived Stem Cells in the field of Plastic Surgery.
10:00 am - 10:15 am
Break
10:15 am - 10:50 am
Basic Stem Cell Line Development: What are the Stem Cells we will be Using in the Next 5 Years?
Yael Porat, Ph.D.
Founder / CEO, BiogenCell, Ltd., Netaya, Israel
The identification of new stem cells types is important to allow physicians to have new tools to treat patients. This lecture will focus on basic stem cell biology including the process of how new stem cells lines are identified and tested.
10:50 am ? 11:35 am
Heart Failure Improvement with Minimal Invasive Delivery of Stem Cell
Jorge Tuma Mubarak, M.D.
Chairman, International Cardiology and Regenerative Medicine, Maison De Sante Clinic, Lima, Peru
Member, Latin American Society of Interventional Cardiology and Latin American Society of Stem Cell Therapy
4 Year follow up reporting on successful retreatment of refractory angina by the use of minimally invasive delivery of stem cells.
11:35 am - 12:15 pm
Bone Marrow Derived Stem Cells In The Treatment Of Diabetes Type 1
Alejandro D. Mesples, M.D.
Interventional Cardiologist Associate Professor of Clinical Research Service, University of Moron, School of Medicine, Argentina
Scientific Advisor and Principal Investigator, Stematix, Houston, TX
The use of bone marrow aspirate concentrate to treat type II and type I diabetes will be discussed. Serum glucose and H1AC levels before and after treatment will be highlighted.
12:15 pm - 1:15 pm
Regulatory Landscape in 2011
Christine Humphrey, Esq and Mitchell Fuerst, Esq
Fuerst, Humphrey & Ittleman Law Firm, Miami, FL
Non-CME Invitation Only Lunch Symposium Sponsored By:
1:15 pm ? 1:45 pm
Improvement After Reimplantation and Parkinson?s Disease Patient Characteristics: Analysis for the Relationships (Relation and Correlation) Between Improvement After reimplantation of Adult Autologpus Bone Marrow Mononuclear Portion Versus Age of Implant, Time of Disease and Age at Diagnosis for Parkinson?s Disease Patients
Tamara Jorquiera, M.D.
Professor, San Martin University, Lima Peru
Physician Researcher, Brazzini Institute of Interventional Radiology
Founding Member, Asociacion Peruana de Terapia Cellular (APTCEL)
The improvements in Parkinson's disease patients after treatment with bone marrow aspirate concentrate will be discussed as well as the correlation between age of implant, time of disease onset, and patient age with treatment success.
1:45 pm ? 2:15 pm
A Validated Method for the Isolation of Adipose Derived Stem Cells and Their Importance in Autologous Fat Graft Survival
Kristin Comella
CEO, Stemlogix, Fort Lauderdale, FL
Chief Scientific Officer, Ageless Regenerative Institute
VP Research & Corporate Development, BioHeart, Inc.
Recent studies have identified adipose tissue as an alternate source of stem cells. The procedure for obtaining adipose derived stem cells (ADSCs) from the patient is a relatively simple process and tolerated by most patients. Fat tissue can usually be found in abundance within the patient?s own body and has a greater number of stem cells than bone marrow. ADSCs can be used at the site of injury or disease, as well as for soft tissue defects and fat transfer. Regenerative cells may amplify the body?s own repair process, accelerate healing, repair damaged and diseased tissue, and prevent scarring and loss of function. ADSCs have demonstrated angiogenic properties and can provide a practical approach to tissue vascularization. We have developed a standardized harvesting process for adipose tissue and the isolation of ADSCs. This advancement in collection of ADSCs makes the procedure more predictable and reliable, which is especially important in treatment of degenerative diseases. These techniques are currently being utilized in the clinic for a variety of indications.
2:15pm - 2:45pm
How Very Small Embryonic Like Stem Cells Shed New Light on Mesenchymal Stem Cell Function - New data supports Role of VSELs TM In The Regenerative Properties of MSCs
Alan G. Harris, M.D., Ph.D.
Vice President Drug Development & Regulatory Affairs, Neostem, New York, NY
Adult multipotent stem cells such as Mesenchymal Stem Cells (MSCs) can differentiate into a limited number of cell types, thus permitting autologous cell-based therapy. This has advantages over human embryonic stem cells (hESC) with no risk of rejection and quicker engraftment. Recently discovered Very Small Embryonic-Like, (VSEL) adult stem cells can be obtained from mobilization and apheresis of autologous peripheral blood thus avoiding the need for bone marrow aspiration.
Current studies suggest that VSELs are true pluripotent stem cells with most of the beneficial, and none of the drawbacks (eg. tumorigenesis), of hESCs or induced pluripotent stem cells. New data supports a role of VSELs in the regenerative properties of MSCs. Unlike other ASCs, pluripotent VSELs can be used for a wide range of therapeutic applications.
Small numbers of VSELs can provide adequate cell doses and are expandable, if necessary, and can be cryopreserved to provide a banked source for multiple regenerative treatments over time, thereby providing a lifelong deposit of pluripotent stem cells. Therapeutic applications of VSELs are being considered in wounds, bone and cartilage repair, cardiovascular diseases and other conditions.
2:45 pm ? 3:15pm
The Use of Mesenchymal Stem cells in Lumbar Degenerative Disc Disease
John R. Schultz, M.D., D.A.B.P.M.
Co-Medical Director, Centeno-Schultz Clinic, Westminster, CO
The results of a 5 year study of the use of BMAC and two different preparations of mesenchymal stem cells to treat lumbar disc bulges will be presented. Before and after high filed MRI's will be reviewed as well as patient reported outcomes will be reviewed.
3:15 pm ? 4:00 pm
Break - Visit Exhibits
4:00 pm - 4:30 pm
Large Scale Outcomes From Peripheral Joint Treatments: Follow Up From the Orthopedic Use of MSCs
Christopher J. Centeno, M.D.
Medical Director, Centeno-Schultz Clinic & Regenerative Science
The lecture will focus on the use of culture expanded mesenchymal stem cells in orthopedics and how percutaneous delivery of these cells can help patient avoid the need for more invasive surgery. Large scale complications will be discussed as well as large case series for knee a hip osteoarthritis outcomes.
4:30 pm ? 4:45pm
Clinical Use of a Single-Setting Autologous Adipose-Derived Stromal Cells Procedure: Lessons Learned To Date
Vasilis Paspaliaris, MD
Director / Founder, Adistem, Hong Kong
Visiting Professor, Institute of Integrative medicine, Indian Open University, Calcutta, India
The presentation will give an introduction into the procedure, how it has evolved into a clinical setting over four years, and where its medical benefits and limitations lie. It will conclude with what the outcome of such clinical research has been.
4:45 pm - 5:30 pm
Adipose Derived Adult Stem Cells: History, Current Use and Future Developments in treating Critical Lim Ischemia
Jeong Chan Ra, D.V.M., Ph.D.
Adjunct Professor, College of Veterinary Medicine, Seoul National University, Seoul South Korea
CEO, RNL Bio Ltd., Seoul, Korea
Adipose derived MSC's hold great promise for regenerative medicine. The use of culture expanded MSC's to treat critical limb ischemia and help patients avoid amputation will be discussed. Before and after photos of treated limbs and vascular studies will be reviewed.
6:00 pm
ICMS Member Meeting & Member Reception